Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists
journal contributionposted on 31.05.2007, 00:00 by Lihu Yang, Gabor Butora, Richard X. Jiao, Alex Pasternak, Changyou Zhou, William H. Parsons, Sander G. Mills, Pasquale P. Vicario, Julia M. Ayala, Margaret A. Cascieri, Malcolm MacCoss
Introduction of ring restrictions to a linear aminobutyramide CC chemokine receptor 2 (CCR2) antagonist lead (2) led to the discovery of a 1,3-disubstituted cyclopentane scaffold with enhanced hCCR2 receptor binding and antagonist activity. (1S,3R)-N-[3,5-Bis(trifluoromethyl)benzyl]-1-methyl-3-[(1R,3‘R)-methyl-1‘H-spiro[indene-1,4‘-piperidin]-1‘-yl]cyclopentanecarboxamide (16) had IC50 of 1.3 nM (binding) and 0.45 nM (functional chemotaxis) against hCCR2. It also showed activity against the mouse CCR2 receptor with an IC50 of 130 nM. Compound 16 is selective against other chemokine receptors, including CCR5 (∼500-fold).